Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review
BackgroundObinutuzumab was approved in China in June 2021 used in combination with chemotherapy (followed by obinutuzumab maintenance) for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL). The clinical application of obinutuzumab has recen...
Saved in:
Main Authors: | Chao Wang, Yunzhuo Dong, Peng Men, Ruixia Zhang, Ying Xiao, Yishan Bu, Yinpeng Qin, Xinran Zhang, Qianqian Dou, Yiheng Yang, Huier Gao, Yi Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1426772/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS
by: Ugo Testa, et al.
Published: (2024-01-01) -
Impact of positive CD4 cells on event‐free survival in follicular lymphoma patients
by: Cong Li, et al.
Published: (2024-09-01) -
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma
by: Jie Zha, et al.
Published: (2025-01-01) -
Baseline [18F]FDG PET/CT radiomics for predicting interim efficacy in follicular lymphoma treated with first-line R-CHOP
by: Zeying Wen, et al.
Published: (2025-01-01) -
The age-adjusted international prognostic index 2 (A-FLIPI2) for elderly patients with follicular lymphoma
by: Jiesong Wang, et al.
Published: (2025-02-01)